

3 March 2026

Lung Cancer figures

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) <5
- Amivantamab Monotherapy 0
- Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) 0
- Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel <5
- Atezolizumab monotherapy (subcutaneous injection only) 0
- Dabrafenib + Trametinib 0
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0
- Durvalumab <5
- Gemcitabine 0
- Nintedanib + Docetaxel 0
- Nivolumab 0
- Osimertinib <5
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 0
- Paclitaxel 0
- Pembrolizumab Monotherapy 17
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 0
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 5
- Pemetrexed + Platinum (Carboplatin/Cisplatin) <5
- RET Inhibitors (Pralsetinib, Selpercatinib) 0
- Sotorasib 0
- Tepotinib 0
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 8

3 March 2026

- Other active systemic anti-cancer therapy see below
 - Gemcitabine & Carboplatin <5
 - Osimertinib&Pemetrexed/Carboplatin <5
 - Paclitaxel&Carboplatin <5
 - Paclitaxel&Carboplatin XRT <5
 - Pembrolizumab/Gemcitabine/Carbo <5
- Palliative care only Not available on RISOH
- Amivantamab with carboplatin and pemetrexed 0
- Cemiplimab with platinum-based chemotherapy 0
- Adagrasib 0
- Datopotamab deruxtecan 0
- Amivantamab with Lazertinib 0

Q2. Does your trust participate in any clinical trials for Non Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.

Open Trials - Belfast Trust 09/02/26		
Project Short title	Project Full title	Recruited (org)
CONCORDE	A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer	<5
PRINCE (TOURIST Platform)	PRINCE: Prospective, randomised, multicentre trial of first line systemic treatment and radiotherapy in stage IV non-small cell lung cancer	<5
QUARTZ LUNG (TOURIST Platform)	QUARTZ LUNG: Quality of life after radiotherapy treatment for patients with stage IV non-small cell lung cancer	0
REFINE-Lung	A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design	0

As the numbers involved are fewer than five (<5), disclosure of this level of detail could lead to the identification of individuals involved. This information is therefore exempt under Section 40(2) of the Freedom of Information Act 2000 (personal information relating to a third party), as disclosure would breach the UK GDPR and Data Protection Act 2018.